Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C77893
http://purl.obolibrary.org/obo/NCIT_C77893
|
|---|---|
| Preferred Name | c-Met Inhibitor JNJ-38877605 |
| Definitions |
An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. c-Met inhibitor JNJ-38877605 selectively inhibits c-Met, a receptor tyrosine kinase (RTK) involved in cancer cell survival and invasiveness, and tumor angiogenesis. c-Met is also known as hepatocyte growth factor receptor (HGFR).
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. c-Met inhibitor JNJ-38877605 selectively inhibits c-Met, a receptor tyrosine kinase (RTK) involved in cancer cell survival and invasiveness, and tumor angiogenesis. c-Met is also known as hepatocyte growth factor receptor (HGFR). |
|---|---|
| prefLabel | c-Met Inhibitor JNJ-38877605
|
| label | c-Met Inhibitor JNJ-38877605
|
| NCI_META_CUI | CL383572
|
| PDQ_Closed_Trial_Search_ID | 594157
|
| code | C77893
|
| prefixIRI | NCIT:C77893
|
| in_subset | |
| Preferred_Name | c-Met Inhibitor JNJ-38877605
|
| FDA_UNII_Code | 15UDG410PN
|
| Contributing_Source | FDA
|
| Maps_To | c-Met Inhibitor JNJ-38877605
|
| CAS_Registry | 943540-75-8
|
| NCI_Drug_Dictionary_ID | 594157
|
| Legacy Concept Name | c-Met_Inhibitor_JNJ-38877605
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 594157
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |